Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

N/AEnrolling By InvitationNCT07660640

Perceive Biotherapeutics, Inc.88 enrolled

Overview

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Interventions

observational studyOTHER

No intervention - observational study

VOY-101BIOLOGICAL

One-time intravitreal injection of VOY-101.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101. 2. Are willing and able to understand and provide informed consent. Exclusion Criteria: There are no exclusion criteria for this study

Locations (4)

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Retina Consultants of Texas

Bellaire, Texas, United States

University of Utah

Salt Lake City, Utah, United States

Sourasky Medical Center - Ichilov

Tel Aviv, Israel

Outcomes

Primary Outcomes

Frequency of ocular and systemic VOY-101 related AEs

Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.